Taisho Pharmaceutical Co., Ltd.
🇯🇵Japan
Clinical Trials
65
Active:5
Completed:52
Trial Phases
4 Phases
Phase 1:22
Phase 2:13
Phase 3:7
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (47.8%)Phase 2
13 (28.3%)Phase 3
7 (15.2%)Not Applicable
4 (8.7%)An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT06849778
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT06837155
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: Triazolam and TS-172Drug: TS-172 and itraconazole
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06837142
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Phase 3
Recruiting
- Conditions
- Hyperphosphatemia Patients on Hemodialysis
- Interventions
- Drug: TS-172 20~60 mg/dayDrug: Placebo
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06745531
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Phase 2
Active, not recruiting
- Conditions
- Hyperphosphatemia Patients on Hemodialysis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT06745518
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found